0001493152-25-022120 | 10-Q | XBRL Viewer

Stock-Based Compensation

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement [Abstract]

Note 8. Stock-Based Compensation

The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards.

In 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as amended, permits the granting of 131,334 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing.

As of September 30, 2025, there were a total of 264,667 shares of Imunon common stock reserved for issuance under the 2018 Plan, which were comprised of 24,986 shares of Imunon common stock subject to equity awards previously granted under the 2018 Plan and 235,509 shares of Imunon common stock available for future issuance under the 2018 Plan. At the 2025 Annual Stockholders Meeting of the Company held on July 11, 2025, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by 133,333 to a total of 264,667 under the 2018 Plan, as amended.

Total compensation cost related to stock options and restricted stock awards was approximately $0.1 million and $0.4 million of expense for the nine months ended September 30, 2025 and 2024, respectively. Of these amounts, approximately $29,000 for the nine months ended September 30, 2025 and $0.2 million expense for the same period ended September 30, 2024 were charged to research and development expenses and $0.1 million of expense for the nine months ended September 30, 2025 and $0.2 million of expense for the nine months ended September 30, 2024 were charged to general and administrative expenses.

A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the nine months ended September 30, 2025 is presented below:

	Stock Options					Restricted Stock Awards				Weighted Average
	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding		Weighted Average Grant Date Fair Value		Contractual Terms of Equity Awards (in years)
Equity awards outstanding at January 1, 2025		107,865		$	28.97		2,647	$	14.85

Equity awards granted		35,693		$	11.44		-	$	-

Equity awards issued		-			-		2,647	$	14.85

Equity awards terminated or forfeited		(118,572	)	$	25.56		-	$	-

Equity awards outstanding at September 30, 2025		24,986		$	20.12		-	$	-		8.8

Equity awards exercisable at September 30, 2025		17,292		$	24.85						8.4

Aggregate intrinsic value of equity awards exercisable at September 30, 2025	$	-

As of September 30, 2025, there was $58,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a period of three 3 to four years. The weighted average grant date fair value of the stock options granted was $11.44 during the nine months ended September 30, 2025.

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:

	For the Nine Months Ended September 30,
	2025			2024
Risk-free interest rate	4.22 to 4.55		%	3.72 to 4.31		%
Expected volatility	110.74 to 123.22		%	101.74 to 115.81		%
Expected life (in years)	9.0 to 10.0			9.0 to 10.0
Expected dividend yield		0.0	%		0.0	%

Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk-free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 5,250,929	$ 5,872,767
Advances and deposits on clinical programs and other current assets	2,006,756	2,136,192
Total current assets	7,257,685	8,008,959
Property and equipment (at cost, less accumulated depreciation and amortization)	601,425	541,272
Other assets:
Operating lease right-of-use assets, net	1,078,623	1,117,133
Deposits and other assets	50,000	50,000
Total other assets	1,128,623	1,167,133
Total assets	8,987,733	9,717,364
Current liabilities:
Accounts payable – trade	1,126,826	1,300,026
Other accrued liabilities	2,676,951	3,033,747
Operating lease liabilities - current portion	394,135	452,358
Total current liabilities	4,197,912	4,786,131
Operating lease liabilities - non-current portion	708,097	686,935
Total liabilities	4,906,009	5,473,066
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at September 30, 2025 and December 31, 2024)
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at September 30, 2025 and December 31, 2024, respectively); 2,896,275 and 966,714 shares issued at September 30, 2025 and December 31, 2024, respectively; and 2,896,273 and 966,712 shares outstanding at September 30, 2025 and December 31, 2024, respectively)	28,963	9,667
Additional paid-in capital	421,213,171	411,122,863
Accumulated deficit	(417,075,222)	(406,803,044)
Total stockholders’ equity before treasury stock	4,166,912	4,329,486
Treasury stock, at cost (2 shares at September 30, 2025 and December 31, 2024)	(85,188)	(85,188)
Total stockholders’ equity	4,081,724	4,244,298
Total liabilities and stockholders’ equity	$ 8,987,733	$ 9,717,364

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	350,000,000	112,500,000
Common stock, shares issued	2,896,275	966,714
Common stock, shares outstanding	2,896,273	966,712
Treasury stock, shares	2	2

Schedule of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Research and development expenses	$ 1,899,251	$ 3,293,209	$ 5,291,297	$ 9,406,715
General and administrative expenses	1,576,577	1,668,258	5,097,694	5,579,549
Total operating expenses	3,475,828	4,961,467	10,388,991	14,986,264
Loss from operations	$ (3,475,828)	$ (4,961,467)	(10,388,991)	(14,986,264)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Change Increase (Decrease), Research and development expenses			(4,116,000)
Research and development expenses			$ 5,291,000	9,407,000
Change Increase (Decrease), Research and development expenses, percentage			(43.80%)
General and administrative expenses			$ 5,098,000	5,580,000
Change Increase (Decrease), General and administrative expenses			$ (482,000)
Change Increase (Decrease), General and administrative expenses, percentage			(8.60%)
Total operating expenses			$ 10,389,000	14,987,000
Change Increase (Decrease), Operating expenses			$ (4,598,000)
Change Increase (Decrease), Operating expenses, percentage			(30.70%)
Loss from operations			$ (10,389,000)	(14,987,000)
Change Increase (Decrease), Loss from operations			$ (4,598,000)
Change Increase (Decrease), Loss from operations, percentage			(30.70%)
Operating Segments [Member] \| Clinical Research [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 2,336,000	4,451,000
Change Increase (Decrease), Research and development expenses			$ (2,115,000)
Change Increase (Decrease), Subtotal, percentage			(47.50%)
Operating Segments [Member] \| Clinical Research [Member] \| OVATION 2 and MRD Trials [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 212,000	1,139,000
Change Increase (Decrease), Research and development expenses			$ (927,000)
Change Increase (Decrease), Subtotal, percentage			(81.40%)
Operating Segments [Member] \| Clinical Research [Member] \| Ovation Three [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 695,000
Change Increase (Decrease), Research and development expenses			$ 695,000
Change Increase (Decrease), Subtotal, percentage
Operating Segments [Member] \| Clinical Research [Member] \| Placcine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 42,000	1,412,000
Change Increase (Decrease), Research and development expenses			$ (1,370,000)
Change Increase (Decrease), Subtotal, percentage			(97.00%)
Operating Segments [Member] \| Clinical Research [Member] \| Other Clinical and Regulatory [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 1,387,000	1,900,000
Change Increase (Decrease), Research and development expenses			$ (513,000)
Change Increase (Decrease), Subtotal, percentage			(27.00%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 2,955,000	4,956,000
Change Increase (Decrease), Research and development expenses			$ (2,001,000)
Change Increase (Decrease), Subtotal, percentage			(40.40%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Placcine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal				2,554,000
Change Increase (Decrease), Research and development expenses			$ (2,554,000)
Change Increase (Decrease), Subtotal, percentage
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Ovation [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 2,209,000	851,000
Change Increase (Decrease), Research and development expenses			$ 1,358,000
Change Increase (Decrease), Subtotal, percentage			159.60%
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Manufacturing (CMC) [Member]
Segment Reporting Information [Line Items]
Subtotal			$ 746,000	$ 1,551,000
Change Increase (Decrease), Research and development expenses			$ (805,000)
Change Increase (Decrease), Subtotal, percentage			(51.90%)

Leases (Details Narrative)	1 Months Ended			9 Months Ended
Leases (Details Narrative)	Apr. 30, 2025 USD ($) ft²	Aug. 31, 2023 USD ($) ft²	Jan. 31, 2023 USD ($) ft²	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Apr. 01, 2026 ft²
Lessee, Lease, Description [Line Items]
Operating lease, cost				$ 402,384	$ 479,401
Operating lease, payments				$ 400,936	$ 488,047
Lawrenceville New Jersey Lease [Member]
Lessee, Lease, Description [Line Items]
Operating lease, term		24 months
Area of land \| ft²	4,359	9,850
Lawrenceville New Jersey Lease [Member] \| Forecast [Member]
Lessee, Lease, Description [Line Items]
Area of land \| ft²						4,011
Lawrenceville New Jersey Lease [Member] \| Minimum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent	$ 10,361	$ 22,983
Lawrenceville New Jersey Lease [Member] \| Maximum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent	$ 10,863	$ 23,394
Huntsville Alabama Lease [Member]
Lessee, Lease, Description [Line Items]
Operating lease, term			60 months
Area of land \| ft²			11,420
Huntsville Alabama Lease [Member] \| Minimum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent			$ 28,550
Huntsville Alabama Lease [Member] \| Maximum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent			$ 30,903

Basis of Presentation

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Note 2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions have been eliminated in consolidation. During the quarter and nine-month period ended September 30, 2025, there were no changes to the Company’s accounting policies. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the nine months ended September 30, 2025 and 2024 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on February 27, 2025.

The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amounts reported in the Company’s condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the unaudited condensed consolidated financial statements and accompanying notes.

Going Concern Uncertainty

Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s drug candidates, and applications and submissions to the U.S. Food and Drug Administration (“FDA”). The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the nine months ended September 30, 2025, the Company had a net loss of $10.3 million and used $10.2 million to fund operations. As of September 30, 2025, the Company has incurred approximately $419 million of cumulative net losses. As of September 30, 2025, the Company had $5.3 million in cash and cash equivalents to fund its operations.

The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the recent tariff announcement by the U.S. federal government, the Russian invasion of Ukraine and the unrest in the Middle East. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these unaudited condensed consolidated financial statements.

The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals.

A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives:

	●	it has assessed its current expenditures and will reduce spending where necessary;

	●	it will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities;

	●	it will pursue possible partnerships and collaborations; and

	●	it will pursue potential out licensing for its drug candidates.

The Company’s ability to continue as a going concern will depend on its ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, the Company’s current capital is not expected to be sufficient to fund operations for the next twelve months.

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, 2024, includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern.

Management’s plan includes private or public equity financings, collaborations, or other strategic transactions such as raising funds from outside investors via its ATM program and other potential funding sources. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company. If the Company is unable to obtain sufficient capital to fund its operations it may be required to evaluate alternatives. The Company’s condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, minimum	4.22%	3.72%
Risk-free interest rate, maximum	4.55%	4.31%
Expected volatility, minimum	110.74%	101.74%
Expected volatility, maximum	123.22%	115.81%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	9 years	9 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	10 years	10 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. Commitments and Contingencies

The Company is not currently a party to any material legal proceedings.

Warrants

9 Months Ended

Sep. 30, 2025

Warrants

Warrants

Note 9. Warrants

The following is a summary of all warrant activity for the nine-month period ended September 30, 2025:

Schedule of Warrant Activity

Warrants	Number of Warrants Issued			Weighted Average Exercise Price

Warrants outstanding at January 1, 2025		395,224		$	32.74

Warrants issued		1,475,838			4.54

Warrants exercised – cashless		(223,946	)		-

Warrants exercised		(671,732	)		5.16

Warrants expired		(10,137	)		242.61

Warrants outstanding at September 30, 2025		965,247		$	8.18

Aggregate intrinsic value of outstanding warrants at September 30, 2025	$	-

Weighted average remaining contractual terms at September 30, 2025		2.8 years

Schedule of Lease Payments and Maturity of Operating Lease Liabilities (Details)	Sep. 30, 2025 USD ($)
Leases
2025	$ 120,196
2026	488,821
2027	498,086
2028	149,896
Subtotal future lease payments	1,256,999
Less imputed interest	(154,767)
Total lease liabilities	$ 1,102,232
Operating lease, weighted average remaining lease term	2 years 7 months 6 days
Operating lease, weighted average discount rate, percent	9.98%

Stockholders’ Equity (Details Narrative) - USD ($)									1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Jul. 25, 2025	Jul. 22, 2025	Jun. 02, 2025	May 23, 2025	May 12, 2025	Sep. 03, 2024	Jul. 30, 2024	May 15, 2024	Nov. 13, 2025	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Jul. 28, 2025	Jul. 11, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues		$ 79,075,969						$ 75,000,000.0		$ 3,472,820	$ 6,436,547	$ 9,063,715
Stock issued, shares		2,121,895	2,100,291
Share price	$ 1.00		$ 37.65
Reverse stock split	15-for-1 reverse stock split
Common stock, shares issued	15									2,896,275	2,896,275		966,714
Common stock, shares outstanding	15									2,896,273	2,896,273		966,712
Reverse stock split shares	31,828,447
Number of authorized shares of common stock										350,000,000	350,000,000		112,500,000
Stock dividend percentage														15.00%
Dividend per share														$ 0.15
Proceeds from issuance of common stock		$ 1,815,267				$ 5,500,000					$ 6,437,251	9,063,715
Prospectus supplement covers aggregate shares		8,184,733
Remaining amount		3,684,733
Additional prospectus supplement amount		4,500,000
Common stock par value										$ 0.01	$ 0.01		$ 0.01
July 2024 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares					333,334
Common stock par value					$ 0.01
Warrants outstanding					194,734
Common stock outstanding percentage					19.98%
Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from issuance of common stock		5,500,000
At the Market Offering Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues		$ 4,500,000						$ 5,500,000
Share price		$ 0.01
Number of shares sold											551,265		5,932
Proceeds from sale of stock											$ 3,638,767		$ 99,506
At the Market Offering Agreement [Member] \| Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold									174,081
Proceeds from sale of stock									$ 816,030
Securities Purchase Agreement [Member] \| July 2024 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares							333,334
Share price							$ 30.00
Proceeds from issuance of common stock							$ 10,000,000.0
Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares				185,186
Proceeds from issuance of common stock				$ 3,300,000
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options outstanding	$ 1,900,000
Stock awards reduced	12,700,000													$ 800,000
Number of authorized shares of common stock															350,000,000
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options outstanding	100,000
Stock awards reduced	$ 800,000													$ 1,000,000.0
Number of authorized shares of common stock															112,500,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues										$ 5,433	$ 10,328	$ 3,393
Stock issued, shares										543,265	1,032,752	339,254
Reverse stock split shares	2,121,942									70,448	70,448
Warrant [Member] \| Securities Purchase Agreement [Member] \| July 2024 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares							333,334
Share price							$ 30.00
Warrant [Member] \| Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares				962,964
Share price				$ 6.75
Pre Funded [Member] \| Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares				296,297
Share price				$ 0.0001
Placement Agents Warrant [Member] \| Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares				24,075
Share price				$ 8.44

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2023	$ 6,266	$ 401,588,570	$ (85,188)	$ 60,796	$ (388,182,802)	$ 13,387,642
Balance, shares at Dec. 31, 2023	626,654
Balance, shares at Dec. 31, 2023			2
Net loss					(14,563,017)	(14,563,017)
Sale of equity through equity financing facilities, net of issuance costs	$ 3,393	9,060,322				9,063,715
Sale of equity through equity financing facilities, net of issuance costs, shares	339,254
Issuance of common stock upon exercise of restricted options	$ 8	113				121
Issuance of common stock upon exercise of restricted options, shares	807
Stock-based compensation expense		364,056				364,056
Realized and unrealized losses, net, on investments securities				(60,796)		(60,796)
Balance at Sep. 30, 2024	$ 9,667	411,013,061	$ (85,188)		(402,745,819)	8,191,721
Balance, shares at Sep. 30, 2024	966,715
Balance, shares at Sep. 30, 2024			2
Balance at Jun. 30, 2024	$ 6,267	401,720,499	$ (85,188)		(397,900,344)	3,741,234
Balance, shares at Jun. 30, 2024	626,727
Balance, shares at Jun. 30, 2024			2
Net loss					(4,845,475)	(4,845,475)
Issuance of common stock upon exercise of restricted options	$ 7	103				110
Issuance of common stock upon exercise of restricted options, shares	734
Stock-based compensation expense		232,137				232,137
Realized and unrealized losses, net, on investments securities	$ 3,393	9,060,322				9,063,715
Realized and unrealized gains (losses), net, on investments securities, shares	339,254
Balance at Sep. 30, 2024	$ 9,667	411,013,061	$ (85,188)		(402,745,819)	8,191,721
Balance, shares at Sep. 30, 2024	966,715
Balance, shares at Sep. 30, 2024			2
Balance at Dec. 31, 2024	$ 9,667	411,122,863	$ (85,188)		(406,803,044)	$ 4,244,298
Balance, shares at Dec. 31, 2024	966,712
Balance, shares at Dec. 31, 2024			2			2
Net loss					(10,272,178)	$ (10,272,178)
Effect of reverse stock split	$ 704					704
Effect of reverse stock split, shares	70,448
Sale of equity through equity financing facilities, net of issuance costs	$ 10,328	6,426,219				6,436,547
Sale of equity through equity financing facilities, net of issuance costs, shares	1,032,752
Issuance of common stock upon exercise of common stock warrants	$ 4,826	3,462,869				3,467,695
Issuance of common stock upon exercise of common stock warrants, shares	482,550
Stock dividend, net of offering costs	$ 3,304	(13,581)				(10,277)
Stock dividend, net of offering costs, shares	330,397
Shares issued to satisfy certain obligations	$ 108	98,932				99,040
Shares issued to satisfy certain obligations, shares	10,767
Issuance of common stock upon exercise of restricted options	$ 26					26
Issuance of common stock upon exercise of restricted options, shares	2,647
Stock-based compensation expense		115,869				115,869
Balance at Sep. 30, 2025	$ 28,963	421,213,171	$ (85,188)		(417,075,222)	$ 4,081,724
Balance, shares at Sep. 30, 2025	2,896,273
Balance, shares at Sep. 30, 2025			2			2
Balance at Jun. 30, 2025	$ 17,175	416,373,961	$ (85,188)		(413,646,098)	$ 2,659,850
Balance, shares at Jun. 30, 2025	1,717,502
Balance, shares at Jun. 30, 2025			2
Net loss					(3,429,124)	(3,429,124)
Effect of reverse stock split	$ 704					704
Effect of reverse stock split, shares	70,448
Sale of equity through equity financing facilities, net of issuance costs	$ 5,433	3,467,387				3,472,820
Sale of equity through equity financing facilities, net of issuance costs, shares	543,265
Issuance of common stock upon exercise of common stock warrants	$ 2,223	1,497,777				1,500,000
Issuance of common stock upon exercise of common stock warrants, shares	222,227
Stock dividend, net of offering costs	$ 3,304	(13,581)				(10,277)
Stock dividend, net of offering costs, shares	330,397
Shares issued to satisfy certain obligations	$ 108	98,932				99,040
Shares issued to satisfy certain obligations, shares	10,767
Issuance of common stock upon exercise of restricted options	$ 16					16
Issuance of common stock upon exercise of restricted options, shares	1,667
Stock-based compensation expense		(211,305)				(211,305)
Balance at Sep. 30, 2025	$ 28,963	$ 421,213,171	$ (85,188)		$ (417,075,222)	$ 4,081,724
Balance, shares at Sep. 30, 2025	2,896,273
Balance, shares at Sep. 30, 2025			2			2

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Segment Performance Measures and Expenses (Details Narrative)	9 Months Ended
	Sep. 30, 2025 Segment
Segment Reporting [Abstract]
Number of operating segment	1
Number of reportable segment	1

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2018
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Research and development expenses	$ 1,899,251	$ 3,293,209	$ 5,291,297	$ 9,406,715
General and administrative expenses	1,576,577	$ 1,668,258	5,097,694	5,579,549
Unrecognized compensation cost	$ 58,000		$ 58,000
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Cost recognized period			3 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Cost recognized period			4 years
Equity Stock Awards [Member] \| Granted Under 2018 Plan and 2007 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance	24,986		24,986
Equity Stock Awards [Member] \| 2018 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock	264,667		264,667
Stock Options and Restricted Stock Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation			$ 100,000	400,000
Stock Options and Restricted Stock Awards [Member] \| Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Research and development expenses			29,000	200,000
Stock Options and Restricted Stock Awards [Member] \| General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
General and administrative expenses			$ 100,000	$ 200,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value per share			$ 11.44
2018 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized					131,334
Common stock, reserved for future issuance	264,667		264,667
Shares available for issuance	235,509		235,509
Number of shares common stock	133,333		133,333

Segment Performance Measures and Expenses (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Significant Expense Categories and Consolidated Net Loss

The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	2025			2024
	For the nine months ended September 30,
	(In thousands)						Change Increase (Decrease)
	2025			2024
Operating Expenses:
Clinical Research
OVATION 2 and MRD Trials	$	212		$	1,139		$	(927	)	(81.4	)%
OVATION 3 Trial		695			-			695		-	%
PlaCCine Vaccine Phase 1 Trial		42			1,412			(1,370	)	(97.0	)%
Other Clinical and Regulatory		1,387			1,900			(513	)	(27.0	)%
Subtotal		2,336			4,451			(2,115	)	(47.5	)%
Non-Clinical R&D and CMC
OVATION Program		2,209			851			1,358		159.6	%
PlaCCine Vaccine Program		-			2,554			(2,554	)	-	%
Manufacturing (CMC)		746			1,551			(805	)	(51.9	)%
Subtotal		2,955			4,956			(2,001	)	(40.4	)%
Research and development expenses		5,291			9,407			(4,116	)	(43.8	)%
General and administrative expenses		5,098			5,580			(482	)	(8.6	)%
Total operating expenses		10,389			14,987			(4,598	)	(30.7	)%
Loss from operations	$	(10,389	)	$	(14,987	)	$	(4,598	)	(30.7	)%

Stockholders’ Equity

9 Months Ended

Sep. 30, 2025

Equity [Abstract]

Stockholders’ Equity

Note 7. Stockholders’ Equity

On May 15, 2024, the Company filed with the U.S. Securities and Exchange Commission (“SEC”) a shelf registration statement on Form S-3 (the “2024 Registration Statement”) for the offer and sale of up to $75 million of its securities. The 2024 Registration Statement was declared effective on May 22, 2024. The 2024 Registration Statement is intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. As noted in the prospectus supplement that the Company filed on July 22, 2025, the aggregate market value of outstanding Common Stock held by non-affiliates was approximately $79,075,969, based on 2,121,895 shares of Common Stock outstanding as of July 22, 2025, of which 2,100,291 shares were held by non-affiliates, and a price of $37.65 per share, which was the last reported sale price of Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”) on June 2, 2025. As a result, the Company’s public float increased above $75.0 million, and the Company is no longer subject to the limitations contained in General Instruction I.B.6 of Form S-3.

Reverse Stock Split

On July 25, 2025, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of 12:01 a.m. ET on July 25, 2025. As of that date, each 15 shares of issued and outstanding common stock and equivalents were consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on July 25, 2025, the Company’s common stock started trading under a new CUSIP number 15117N701 although the Company’s ticker symbol, IMNN, remained unchanged.

The reverse stock split was previously approved by the Company’s stockholders at the 2025 Annual Meeting held on July 11, 2025, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment are:

	●	To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of Common Stock; and

	●	To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share.

Immediately prior to the reverse stock split, the Company had 31,828,447 shares of common stock outstanding which consolidated into 2,121,942 shares of the Company’s common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares were rounded up to the nearest whole share. The reverse stock split did not impact the total authorized number of shares of common or preferred stock or the par value thereof. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately 1.9 million to approximately 0.1 million and outstanding warrants being reduced from approximately 12.7 million to approximately 0.8 million.

Increase to Authorized Shares

At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company held on July 11, 2025, upon the recommendation of the Company’s board of directors, the Company’s stockholders voted on and approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 112,500,000 shares to 350,000,000 shares, and to make a corresponding change to the number of authorized shares of capital stock. Such amendment became effective on July 11, 2025 upon filing with the Secretary of State of the State of Delaware.

Stock Dividend

On July 28, 2025, the Company announced that the Company’s Board of Directors approved a 15% stock dividend, 0.15 shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock and per each common stock equivalent with dividend rights.

The Board of Directors fixed August 7, 2025 as the record date (the “Record Date”) for the Stock Dividend, and the Stock Dividend was issued on August 21, 2025 to stockholders of record as of the Record Date.

The number of outstanding warrants were adjusted accordingly, with outstanding warrants increasing from approximately 0.8 million to approximately 1.0 million.

At the Market Offering Agreement

On May 15, 2024, the Company amended the At the Market Offering Agreement, dated as of May 25, 2022 (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) as sales agent. Pursuant to the terms of the amended ATM Agreement, the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $5,500,000. The Company intends to use the net proceeds from any offering under the amended ATM Agreement for general corporate purposes, including research and development activities, capital expenditures and working capital.

On July 30, 2024, the Company notified Wainwright that it was suspending its use of and terminating the “at the market offering” sales agreement prospectus (the “ATM Prospectus”), related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM Agreement, by and between the Company and Wainwright. Notwithstanding the termination of the ATM Prospectus, the ATM Agreement remains in full force and effect.

On September 3, 2024, the Company filed a new prospectus supplement to the 2024 Registration Statement with the SEC for an aggregate offering price of up to $5,500,000 related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM Agreement with Wainwright as sales agent.

On July 22, 2025, the Company filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $4,500,000 of shares of the Company’s common stock, par value $0.01 per share issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC, as sales agent or principal (the “Sales Agent”). The Company previously registered the offer and sale of up to $5,500,000 of shares of Common Stock through the Sales Agent under the Sales Agreement. Prior to the date hereof, the Company has sold an aggregate of $1,815,267 shares of Common Stock through the Sales Agent under the Sales Agreement. Accordingly, the Prospectus Supplement covers an aggregate of $8,184,733 of Shares, consisting of $3,684,733 remaining of the amount originally registered and the additional $4,500,000 increase under the Prospectus Supplement.

The Company sold 5,932 shares of common stock under the ATM Agreement for net proceeds of $99,506 during 2024. During 2025, the Company sold 551,265 shares of common stock under the ATM Agreement for net proceeds of $3,638,767 through September 30, 2025. The Company sold 174,081 shares of common stock under the ATM Agreement for net proceeds of $816,030 subsequent to September 30, 2025.

July 2024 Offering

On July 30, 2024, the Company entered into the July 2024 Purchase Agreement with the Purchasers, pursuant to which the Company issued, in a registered direct offering, an aggregate of 333,334 shares of the Company’s common stock at an offering price of $30.00 per share for gross proceeds of $10.0 million before the deduction of placement agent fees and offering expenses. In a concurrent private placement and also pursuant to the July 2024 Purchase Agreement, the Company issued to the Purchasers the Warrants to purchase an aggregate of 333,334 shares of its common stock at an exercise price of $30.00 per share.

The Warrants became exercisable immediately after issuance for a term of five and one-half years following the date of issuance. The closing of the July 2024 Offering occurred on August 1, 2024.

On May 12, 2025, the Company entered into an exchange agreement (the “Agreement”) with the holders (the “Warrant Holders”) of certain warrants of the Company issued on August 1, 2024, which are exercisable for an aggregate of 333,334 shares of the Company’s common stock, par value $0.01 per share. Pursuant to the terms of the Agreement, the Company will issue to the Warrant Holders an aggregate of 194,734 shares of Common Stock (the “Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable under the Warrants (the “Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Agreement, the Warrant Holders also agreed to waive the Company’s compliance with the provisions of Section 4.12(b) of the Securities Purchase Agreement, dated July 30, 2024, with respect to any Company Variable Rate Transaction (as defined in the Purchase Agreement) for a period of forty-five (45) days from the date of the Agreement and agreed to a lock up period on the Warrant Exchange Shares ending on the opening of trading on May 14, 2025. The Warrant Exchange closed on May 13, 2025. The number of Warrant Exchange Shares that will be issued pursuant to the Agreement will represent 19.98% of the shares of Common Stock outstanding as of the date of the Agreement.

May 2025 Offering

On May 23, 2025, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors, for the issuance and sale in a private placement of (i) 185,186 shares of the Company’s common stock, (ii) 296,297 of pre-funded warrants at an exercise price of $0.0001 per share and (iii) 962,964 warrants at an exercise price of $6.75 per share for gross proceeds of approximately $3.3 million before the deduction of placement agent fees and offering expenses.

The Prefunded Warrants became exercisable immediately after issuance for a term of two and one-half years following the date of issuance. The Warrants will be exercisable upon receipt of such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the shares of Common Stock upon the exercise thereof (“Stockholder Approval,” and such date, the “Stockholder Approval Date”) and have a term of three years. The prefunded warrants were exercised in full on June 16, 2025 and June 18, 2025.

In addition, the Company issued to H.C. Wainwright & Co., LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 24,075 shares of common stock at an exercise price equal to $8.44 per share. The Placement Agent Warrants have substantially the same terms as the Warrants. The closing of the May 2025 Offering occurred on May 28, 2025. On July 11, 2025, the Company’s stockholders approved the issuance of the Warrants.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Leases (Tables)

9 Months Ended

Sep. 30, 2025

Leases

Schedule of Lease Payments and Maturity of Operating Lease Liabilities

The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of September 30, 2025:


2025	$	120,196
2026		488,821
2027		498,086
2028		149,896
Subtotal future lease payments		1,256,999
Less imputed interest		(154,767	)
Total lease liabilities	$	1,102,232

Weighted average remaining life		2.6

Weighted average discount rate		9.98	%

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Basis of Presentation (Details Narrative) - USD ($)	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 3,429,124	$ 4,845,475	$ 10,272,178	$ 14,563,017
Cash to fund operation			10,239,523	$ 14,433,986
Cumulative net loss	419,000,000		419,000,000
Cash and cash equivalents, short-term investments, and interest receivable	$ 5,300,000		$ 5,300,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Schedule of Other Accrued Liabilities (Details) - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Amounts due to contract research organizations and other contractual agreements	$ 910,501	$ 1,048,036
Accrued payroll and related benefits	1,687,690	1,945,111
Accrued professional fees and other	78,760	40,600
Total	$ 2,676,951	$ 3,033,747

Other Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2025

Payables and Accruals [Abstract]

Schedule of Other Accrued Liabilities

Other accrued liabilities at September 30, 2025 and December 31, 2024 include the following:

Schedule of Other Accrued Liabilities

	September 30, 2025		December 31, 2024
Amounts due to contract research organizations and other contractual agreements	$	910,501	$	1,048,036
Accrued payroll and related benefits		1,687,690		1,945,111
Accrued professional fees and other		78,760		40,600
Total	$	2,676,951	$	3,033,747

New Accounting Pronouncements

9 Months Ended

Sep. 30, 2025

Accounting Changes and Error Corrections [Abstract]

New Accounting Pronouncements

Note 3. New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s condensed consolidated financial position, results of operations, and cash flows, or do not apply to its operations.

In December 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-09, “Improvements to Income Tax Disclosures”, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the unaudited condensed consolidated financial statements; the Company expects changes to the Company’s income tax disclosure.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company’s disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

Warrants (Tables)

9 Months Ended

Sep. 30, 2025

Warrants

Schedule of Warrant Activity

The following is a summary of all warrant activity for the nine-month period ended September 30, 2025:

Schedule of Warrant Activity

Warrants	Number of Warrants Issued			Weighted Average Exercise Price

Warrants outstanding at January 1, 2025		395,224		$	32.74

Warrants issued		1,475,838			4.54

Warrants exercised – cashless		(223,946	)		-

Warrants exercised		(671,732	)		5.16

Warrants expired		(10,137	)		242.61

Warrants outstanding at September 30, 2025		965,247		$	8.18

Aggregate intrinsic value of outstanding warrants at September 30, 2025	$	-

Weighted average remaining contractual terms at September 30, 2025		2.8 years

Segment Performance Measures and Expenses

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Segment Performance Measures and Expenses

Note 5. Segment Performance Measures and Expenses

The Company operates in one segment for the research and development of product candidates. The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company based on condensed consolidated financial information. Consequently, the Company views the entire organization as one reportable segment and the strategic purpose of all operating activities (including general and administrative expenses) is to support that one segment. As a pre-revenue research and development company, the CODM evaluates company-wide performance and allocates resources based on non-financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred. The CODM does not generally evaluate the Company’s performance using asset or historical cash flow information.

The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	2025			2024
	For the nine months ended September 30,
	(In thousands)						Change Increase (Decrease)
	2025			2024
Operating Expenses:
Clinical Research
OVATION 2 and MRD Trials	$	212		$	1,139		$	(927	)	(81.4	)%
OVATION 3 Trial		695			-			695		-	%
PlaCCine Vaccine Phase 1 Trial		42			1,412			(1,370	)	(97.0	)%
Other Clinical and Regulatory		1,387			1,900			(513	)	(27.0	)%
Subtotal		2,336			4,451			(2,115	)	(47.5	)%
Non-Clinical R&D and CMC
OVATION Program		2,209			851			1,358		159.6	%
PlaCCine Vaccine Program		-			2,554			(2,554	)	-	%
Manufacturing (CMC)		746			1,551			(805	)	(51.9	)%
Subtotal		2,955			4,956			(2,001	)	(40.4	)%
Research and development expenses		5,291			9,407			(4,116	)	(43.8	)%
General and administrative expenses		5,098			5,580			(482	)	(8.6	)%
Total operating expenses		10,389			14,987			(4,598	)	(30.7	)%
Loss from operations	$	(10,389	)	$	(14,987	)	$	(4,598	)	(30.7	)%

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Subsequent Events

9 Months Ended

Sep. 30, 2025

Subsequent Events [Abstract]

Subsequent Events

Note 12. Subsequent Events

The Company has evaluated its subsequent events from September 30, 2025, through the date these condensed consolidated financial statements were issued.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (10,272,178)	$ (14,563,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	216,830	202,938
Amortization of right-of-use assets	312,805	349,892
Realized losses, net, on investment securities		(61,983)
Stock-based compensation	115,895	364,177
Shares issued in exchange for services	99,040
Realization of deferred income tax asset		1,280,385
Net changes in:
Advances, deposits, and other current assets	129,436	324,580
Accounts payable and accrued liabilities	(841,351)	(2,330,958)
Net cash used in operating activities	(10,239,523)	(14,433,986)
Cash flows from investing activities:
Purchases of investment securities		(57,174)
Proceeds from sale and maturity of investment securities		9,915,448
Purchases of property and equipment	(276,983)	(14,634)
Net cash (used in) provided by investing activities	(276,983)	9,843,640
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	6,437,251	9,063,715
Proceeds from issuance of common stock upon exercise of warrants	3,467,694
Issuance costs for stock dividend	(10,277)
Net cash provided by financing activities	9,894,668	9,063,715
Net change in cash and cash equivalents	(621,838)	4,473,369
Cash and cash equivalents at beginning of period	5,872,767	5,838,566
Cash and cash equivalent at end of period	5,250,929	10,311,935
Non-cash investing and financing activities:
Recognition of operating lease right-of-use asset and liability	$ 274,295

Schedule of Stock Options Awards and Restricted Stock Grants (Details)	9 Months Ended
	Sep. 30, 2025 USD ($) $ / shares shares
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding, beginning balance \| shares	107,865
Weighted average exercise price, beginning balance \| $ / shares	$ 28.97
Options outstanding, granted \| shares	35,693
Weighted average exercise price, granted \| $ / shares	$ 11.44
Options outstanding, issued \| shares
Weighted average exercise price, issued \| $ / shares
Equity awards terminated or forfeited \| shares	(118,572)
Equity awards terminated or forfeited \| $ / shares	$ 25.56
Options outstanding, ending balance \| shares	24,986
Weighted average exercise price, ending balance \| $ / shares	$ 20.12
Weighted average contractual terms	8 years 9 months 18 days
Options outstanding, exercisable \| shares	17,292
Weighted average exercise price, exercisable \| $ / shares	$ 24.85
Weighted average contractual terms, exercisable	8 years 4 months 24 days
Options outstanding, aggregate intrinsic value, exercisable \| $
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested stock awards, beginning balance \| shares	2,647
Weighted average grant date fair value, beginning balance \| $ / shares	$ 14.85
Non-vested stock awards, granted \| shares
Weighted average grant date fair value, granted \| $ / shares
Non-vested stock awards, issued \| shares	2,647
Weighted average grant date fair value, issued \| $ / shares	$ 14.85
Non-vested stock awards, Terminated \| shares
Weighted average grant date fair value, Terminated or forfeited \| $ / shares
Non-vested stock awards, ending balance \| shares
Weighted average grant date fair value, ending balance \| $ / shares

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (3,429,124)	$ (4,845,475)	$ (10,272,178)	$ (14,563,017)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Leases

9 Months Ended

Sep. 30, 2025

Leases

Leases

Note 10. Leases

Lawrenceville, New Jersey Lease

In August 2023, the Company renewed its Lawrenceville office lease for a 24-month agreement for 9,850 square feet with monthly rent payments of approximately $22,983 to $23,394. In April 2025, the Company renewed its Lawrenceville office lease until November 30, 2028 for 4,359 square feet (to be reduced to 4,011 following April 1, 2026) with monthly rent payments of approximately $10,361 to $10,863.

Huntsville, Alabama Lease

In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11,420 square feet with monthly rent payments of approximately $28,550 to $30,903.

The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of September 30, 2025:


2025	$	120,196
2026		488,821
2027		498,086
2028		149,896
Subtotal future lease payments		1,256,999
Less imputed interest		(154,767	)
Total lease liabilities	$	1,102,232

Weighted average remaining life		2.6

Weighted average discount rate		9.98	%

For the nine-month period ended September 30, 2025, operating lease expense was $402,384 and cash paid for operating leases included in operating cash flows was $400,936. For the nine-month period ended September 30, 2024, operating lease expense was $479,401 and cash paid for operating leases included in operating cash flows was $488,047.

Business Description

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Business Description

Note 1. Business Description

Imunon, Inc. (“Imunon” or the “Company”) is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase II clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

Schedule of Warrant Activity (Details)	9 Months Ended
Schedule of Warrant Activity (Details)	Sep. 30, 2025 USD ($) $ / shares shares
Warrants
Number of Warrants Issued, Warrants outstanding, Beginning balance \| shares	395,224
Weighted Average Exercise Price, Warrants outstanding, Beginning balance \| $ / shares	$ 32.74
Number of Warrants Issued, Warrants issued \| shares	1,475,838
Weighted Average Exercise Price, Warrants issued \| $ / shares	$ 4.54
Number of Warrants Issued, Warrants exercised cashless \| shares	(223,946)
Weighted Average Exercise Price, Warrants exercised cashless \| $ / shares
Number of Warrants Issued, Warrants exercised \| shares	(671,732)
Weighted Average Exercise Price, Warrants exercised \| $ / shares	$ 5.16
Number of Warrants Issued, Warrants expired \| shares	(10,137)
Weighted Average Exercise Price, Warrants expired \| $ / shares	$ 242.61
Number of Warrants Issued, Warrants outstanding, Ending balance \| shares	965,247
Weighted Average Exercise Price, Warrants outstanding, Ending balance \| $ / shares	$ 8.18
Aggregate intrinsic value of outstanding warrants \| $
Weighted average remaining contractual terms	2 years 9 months 18 days

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development	$ 1,899,251	$ 3,293,209	$ 5,291,297	$ 9,406,715
General and administrative	1,576,577	1,668,258	5,097,694	5,579,549
Total operating expenses	3,475,828	4,961,467	10,388,991	14,986,264
Loss from operations	(3,475,828)	(4,961,467)	(10,388,991)	(14,986,264)
Other income:
Investment income, net	46,704	115,992	116,813	423,247
Total other income, net	46,704	115,992	116,813	423,247
Net loss	$ (3,429,124)	$ (4,845,475)	$ (10,272,178)	$ (14,563,017)
Net loss per common share
Basic	$ (1.16)	$ (3.76)	$ (5.53)	$ (14.13)
Diluted	$ (1.16)	$ (3.76)	$ (5.53)	$ (14.13)
Weighted average shares outstanding
Basic	2,943,655	1,289,823	1,855,922	1,030,622
Diluted	2,943,655	1,289,823	1,855,922	1,030,622

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Options Awards and Restricted Stock Grants

	Stock Options					Restricted Stock Awards				Weighted Average
	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding		Weighted Average Grant Date Fair Value		Contractual Terms of Equity Awards (in years)
Equity awards outstanding at January 1, 2025		107,865		$	28.97		2,647	$	14.85

Equity awards granted		35,693		$	11.44		-	$	-

Equity awards issued		-			-		2,647	$	14.85

Equity awards terminated or forfeited		(118,572	)	$	25.56		-	$	-

Equity awards outstanding at September 30, 2025		24,986		$	20.12		-	$	-		8.8

Equity awards exercisable at September 30, 2025		17,292		$	24.85						8.4

Aggregate intrinsic value of equity awards exercisable at September 30, 2025	$	-

Schedule of Assumptions Used to Determine Fair Value of Options Granted

	For the Nine Months Ended September 30,
	2025			2024
Risk-free interest rate	4.22 to 4.55		%	3.72 to 4.31		%
Expected volatility	110.74 to 123.22		%	101.74 to 115.81		%
Expected life (in years)	9.0 to 10.0			9.0 to 10.0
Expected dividend yield		0.0	%		0.0	%

Cover - $ / shares	9 Months Ended
Cover - $ / shares	Sep. 30, 2025	Nov. 10, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2025
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-15911
Entity Registrant Name	Imunon, Inc.
Entity Central Index Key	0000749647
Entity Tax Identification Number	52-1256615
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	997 Lenox Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lawrenceville
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08648
City Area Code	(609)
Local Phone Number	896-9100
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	IMNN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,070,354
Entity Information, Former Legal or Registered Name	NA
Entity Listing, Par Value Per Share	$ 0.01

Net Loss per Common Share

9 Months Ended

Sep. 30, 2025

Net loss per common share

Net Loss per Common Share

Note 4. Net Loss per Common Share

Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive.

The total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards was 990,233 and 447,499 shares for the nine months ended September 30, 2025 and 2024, respectively. For the nine-month periods ended September 30, 2025 and 2024, diluted loss per common share was the same as basic loss per common share as the other warrants, and equity awards that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted loss per common share as their effect would have been anti-dilutive.

The Company declared a 15% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with Accounting Standards Codification (“ASC”) 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods presented to reflect the effect of this stock dividend. The Company did not pay any dividends during the first nine months of 2024.

Net Loss per Common Share (Details Narrative) - shares		9 Months Ended
Net Loss per Common Share (Details Narrative) - shares	Aug. 07, 2025	Sep. 30, 2025	Sep. 30, 2024
Net loss per common share
Anti-dilutive securities		990,233	447,499
Stock dividend percentage	15.00%

Other Accrued Liabilities

9 Months Ended

Sep. 30, 2025

Payables and Accruals [Abstract]

Other Accrued Liabilities

Note 6. Other Accrued Liabilities

Other accrued liabilities at September 30, 2025 and December 31, 2024 include the following:

Schedule of Other Accrued Liabilities

	September 30, 2025		December 31, 2024
Amounts due to contract research organizations and other contractual agreements	$	910,501	$	1,048,036
Accrued payroll and related benefits		1,687,690		1,945,111
Accrued professional fees and other		78,760		40,600
Total	$	2,676,951	$	3,033,747